18 results on '"Chen, Jingjing"'
Search Results
2. 225 PROGNOSTIC VALUE OF FECAL CALPROTECTIN IN BIOLOGIC-TREATED PATIENTS WITH ULCERATIVE COLITIS
3. Sa1880 DOSE ESCALATION OF SUBCUTANEOUS VEDOLIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS: A POST HOC ANALYSIS OF THE VISIBLE TRIAL DATA
4. Sa1879 EFFICACY AND SAFETY OF VEDOLIZUMAB REINITIATION FOLLOWING TREATMENT INTERRUPTION: POST HOC ANALYSIS OF THE VISIBLE TRIAL DATA
5. Sa1878 POST HOC EXAMINATION OF VISIBLE 1 DATA FOR BASELINE PREDICTORS OF RESPONSE TO 2 OR 3 IV DOSES OF VEDOLIZUMAB FOR ADULTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
6. Sa1831 VEDOLIZUMAB LEVELS IN BREAST MILK: RESULTS FROM A PROSPECTIVE, POSTMARKETING, MILK-ONLY LACTATION STUDY IN NURSING MOTHERS WITH INFLAMMATORY BOWEL DISEASE
7. Sa1792 PATIENT-REPORTED HEALTH-RELATED QUALITY OF LIFE OUTCOMES WITH VEDOLIZUMAB VERSUS ADALIMUMAB TREATMENT OF ULCERATIVE COLITIS: RESULTS OF THE VARSITY TRIAL
8. Su1929 A HYBRID APPROACH OF HANDLING MISSING DATA IN INFLAMMATORY BOWEL DISEASE (IBD) TRIALS: RESULTS FROM VISIBLE 1 AND VARSITY
9. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis
10. Sa1878 – Effects of Subcutaneous Vedolizumab on Health-Related Quality of Life and Work Productivity in Patients with Ulcerative Colitis: Results from the Phase 3 Visible 1 Trial
11. 416a – Vedolizumab Shows Superior Efficacy Versus Adalimumab: Results of Varsity—The First Head-To-Head Study of Biologic Therapy for Moderate-To-Severe Ulcerative Colitis
12. Su1924 – The Use of Alvimopan As Prophylaxis Against Post-Operative Ileus After Bowel Resection in Patients with Inflammatory Bowel Disease
13. Tu1713 – Efficacy and Safety of 2 Or 3 Vedolizumab Intravenous Infusions As Induction Therapy for Ulcerative Colitis and Crohn's Disease: Results from Visible 1 and 2
14. Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn’s Disease: A Phase 2a Study
15. Cationic Polystyrene Resolves Nonalcoholic Steatohepatitis (NASH), Obesity,and Metabolic Disorders in an Animal Model by Promoting Eubiosis of Gut Microbiota and Decreasing Endotoxemia
16. 830 Initial Evaluation of MEDI2070 (Specific Anti-IL-23 Antibody) in Patients With Active Crohn's Disease Who Have Failed Anti-TNF Antibody Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 2A Induction Study
17. Tu1941 - Cationic Polystyrene Resolves Nonalcoholic Steatohepatitis (NASH), Obesity,and Metabolic Disorders in an Animal Model by Promoting Eubiosis of Gut Microbiota and Decreasing Endotoxemia
18. Down-Regulation of Osteopontin Suppresses Growth and Metastasis of Hepatocellular Carcinoma Via Induction of Apoptosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.